IT1237793B - Composti attivi come inibitori dell'enzima hmg-coa reduttasi - Google Patents

Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Info

Publication number
IT1237793B
IT1237793B IT02276889A IT2276889A IT1237793B IT 1237793 B IT1237793 B IT 1237793B IT 02276889 A IT02276889 A IT 02276889A IT 2276889 A IT2276889 A IT 2276889A IT 1237793 B IT1237793 B IT 1237793B
Authority
IT
Italy
Prior art keywords
hmg
inhibitors
active compounds
coa reductase
reductase enzyme
Prior art date
Application number
IT02276889A
Other languages
English (en)
Other versions
IT8922768A1 (it
IT8922768A0 (it
Inventor
Giorgio Bertolini
Cesare Casagrande
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT02276889A priority Critical patent/IT1237793B/it
Publication of IT8922768A0 publication Critical patent/IT8922768A0/it
Priority to EP19900123761 priority patent/EP0433842A3/en
Priority to US07/626,762 priority patent/US5081136A/en
Priority to JP2418293A priority patent/JPH04210682A/ja
Publication of IT8922768A1 publication Critical patent/IT8922768A1/it
Application granted granted Critical
Publication of IT1237793B publication Critical patent/IT1237793B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT02276889A 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi IT1237793B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EP19900123761 EP0433842A3 (en) 1989-12-21 1990-12-11 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
US07/626,762 US5081136A (en) 1989-12-21 1990-12-13 1,2,3-triazole compounds active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
JP2418293A JPH04210682A (ja) 1989-12-21 1990-12-20 酵素ＨＭＧ−ＣｏＡレダクターゼの抑制剤として活性な化合物ならびに該化合物を含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Publications (3)

Publication Number Publication Date
IT8922768A0 IT8922768A0 (it) 1989-12-21
IT8922768A1 IT8922768A1 (it) 1991-06-21
IT1237793B true IT1237793B (it) 1993-06-17

Family

ID=11200250

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Country Status (4)

Country Link
US (1) US5081136A (it)
EP (1) EP0433842A3 (it)
JP (1) JPH04210682A (it)
IT (1) IT1237793B (it)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1037616C (zh) * 1993-07-15 1998-03-04 中国科学院兰州化学物理研究所 多功能润滑油添加剂
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
CA2398995C (en) * 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
US20020058065A1 (en) * 2000-09-20 2002-05-16 Pol-Henri Guivarc'h Insoluble drug particle compositions with improved fasted-fed effects
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2510320C (en) 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1809759B1 (en) 2004-10-06 2013-09-11 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
WO2006083779A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
NZ563759A (en) 2005-05-31 2010-06-25 Mylan Lab Inc Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
ES2532595T3 (es) 2006-08-30 2015-03-30 Kyushu University, National University Corporation Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
CN101686674A (zh) * 2007-03-01 2010-03-31 康考斯保健科学有限责任公司 肌醇烟酸酯的异构体及其用途
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
WO2009102761A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CA2788571A1 (en) 2010-02-01 2011-08-04 Andrew Redington Remote ischemic conditioning for treatment and prevention of restenosis
EP2552331B1 (en) 2010-03-31 2020-01-08 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
WO2011127341A2 (en) 2010-04-08 2011-10-13 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
BR112013011265A2 (pt) 2010-11-09 2016-11-01 Hoffmann La Roche derivados de triazol como ligantes para receptores gaba
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
EP2879666B1 (en) 2012-08-01 2020-04-08 Tavakoli, Zahra Free flowing, frozen compositions comprising a therapeutic agent
BR112015024234B1 (pt) 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
ES2672993T3 (es) 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Formulaciones de liberación sostenida de anestésicos locales
KR101777634B1 (ko) 2016-01-18 2017-09-12 연성정밀화학(주) 3-((2s,5s)-4-메틸렌-5-(3-옥소프로필)테트라히드로퓨란-2-일)프로판올 유도체의 제조방법 및 이를 위한 중간체
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
WO2021191837A1 (en) 2020-03-26 2021-09-30 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI860755A0 (fi) * 1984-06-22 1986-02-20 Sandoz Ag Pyrazolanaloger av mevolonolakton och deras derivat, foerfaranden foer deras framstaellning samt deras andvaendning.
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4808607A (en) * 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte

Also Published As

Publication number Publication date
IT8922768A1 (it) 1991-06-21
IT8922768A0 (it) 1989-12-21
US5081136A (en) 1992-01-14
EP0433842A3 (en) 1992-01-08
JPH04210682A (ja) 1992-07-31
EP0433842A2 (en) 1991-06-26

Similar Documents

Publication Publication Date Title
IT1237793B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3770345D1 (de) Inhibitoren von hmg-coa-reduktase.
NO882218D0 (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
NO180718C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive mercaptoacetylamidderivater
EP0859614A4 (en) INHIBITOR OF ROTAMASE ENCYMACTIVITY
NO931795L (no) Dobbeltvirkende inhibitorer
MC2313A1 (fr) Inhibiteurs d'enzymes
FI921279A7 (fi) Amino-b-lyaasientsyymin inhibiittorit deodorantteina
EP0567088A3 (en) Process for the preparation of an amylase inhibitor.
MX9203768A (es) Inhibidores novedosos de reductasa 3-hidroxi-metilglutaril-coenzima a.
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3881373D1 (de) Hmg-coa-reduktase-hemmer.
EP0994707A4 (en) INHIBITORS OF NAALADASE ENZYME ACTIVITY
NO882219L (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
MX9100998A (es) Novedosos inhibidores de escualen sintetasa
DE68900988D1 (de) Hmg-coa-reduktase-inhibitoren.
FI893004A7 (fi) 5-oksygenoituja HMG-CoA-reduktaasi-inhibiittoreita
NO932850L (no) Fremgangsmaate for fremstilling av staal
ZA886468B (en) Novel hmg-coa reductase inhibitors
IT8419141A0 (it) Procedimento per la preparazione dell'estere metilico di alfa-l-aspartil-l-fenilalanina.
FI962235L (fi) Uudet bentseenisulfonyyli-imiinijohdannaiset IL-1:n toiminnan inhibiittoreina
FI945290L (fi) Menetelmä ribonukleotidireduktaasi-inhibiittoreiden valmistamista varten
ITMI921854A0 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
NO901422D0 (no) Fremgangsmaate for fremstilling av alfa-glucosidase-inhibitorer.

Legal Events

Date Code Title Description
0001 Granted